Influence of methylprednisolone on the reversal time of sugammadex: a randomized clinical trial

Kocaoglu M. H., MEÇO B. C., ÖZÇELİK M., BATİSLAM Y.

REVISTA BRASILEIRA DE ANESTESIOLOGIA, cilt.70, sa.2, ss.111-117, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 70 Sayı: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.bjan.2020.01.002
  • Dergi Adı: REVISTA BRASILEIRA DE ANESTESIOLOGIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.111-117
  • Anahtar Kelimeler: Sugammadex, Rocuronium, TOF, Methytprednisolone, Recovery, RESIDUAL NEUROMUSCULAR BLOCKADE, POSTEXTUBATION LARYNGEAL EDEMA, BLOCKING-AGENTS, DEXAMETHASONE, PREVENTION, MANAGEMENT
  • Ankara Üniversitesi Adresli: Evet

Özet

Background and objectives: Sugammadex is a modified gamma-cyclodextrin that reverses the effects of aminosteroidal neuromuscular blocking agents. Likewise, some steroid molecules, such as toremifene, fusidic acid, and flucloxacillin, can also be encapsulated by sugammadex. Methylprednisolone, which is a synthetic steroid used commonly for airway oedema prophylaxis, can also be encapsulated by sugammadex. The objective of this study was to compare the recovery times of sugammadex for reversing rocuronium-induced moderate neuromuscular blockade in those who received intraoperative 1 nng.kg(-1) methylprednisolone or saline.